MedinCell
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3 Rue Des Freres Lumiere, Jacou, Occitan...Phone Number
+33 467021367Website
www.medincell.comRevenue
$33.6 MillionStock Symbol
MEDCLIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About MedinCell
MedinCell is a clinical- and commercial-stage biopharmaceutical company headquartered in Montpellier, France, focused on developing long-acting injectable treatments across multiple therapeutic areas. Founded in 2003 and publicly traded on Euronext Paris, the company leverages its proprietary BEPO technology platform to enable controlled, sustained drug delivery over days, weeks, or months following a single subcutaneous or local injection using fully bioresorbable deposits. MedinCell's approach is designed to improve patient adherence, enhance treatment accessibility, and reduce the environmental impact of medicines. Its first FDA-approved product, UZEDY, is a risperidone-based long-acting injectable marketed by Teva Pharmaceuticals for schizophrenia and bipolar I disorder.Explore more
MedinCell Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MedinCell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on MedinCell recently announced quarterly report
MedinCell, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when MedinCell launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if MedinCell had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at MedinCell
Check if MedinCell has recently received funding, and reach out quickly before it becomes old news!
Check out if MedinCell is spiking on competitors!
Funding: Get notified immidiatlly once MedinCell has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined MedinCell as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
MedinCell is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MedinCell is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MedinCell.
MedinCell financials insights
Gather financial insights about MedinCell, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Private Equity
$19M
2020
Debt
$12M
2022
Debt
$40M
2023
Other Financing Round
$27.3M
MedinCell Tech Stack
A closer look at the technologies used by MedinCell
See more technologies
Most Recent Scoops
Project
MedinCell announced that its new drug application for olanzapine LAI was submitted to the FDA in December 2025 and accepted in February 2026, with a marketing authorization application also submitted in Europe, and a US launch expected in Q4 2026, subject to regulatory approval.
Pharmaceuticals
Project
MedinCell has successfully completed a clinical program demonstrating 4,000 injections of its olanzapine long-acting injectable formulation with no Post-Dose Sedation Syndrome events, surpassing the 3,600-injection threshold established in discussions with the FDA to avoid mandatory monitoring constraints.
Pharmaceuticals, Clinical Operations
Project
MedinCell has completed a 700-patient real-world study comparing UZEDY to second-generation oral antipsychotics, with results demonstrating a 42% reduction in relapse rates, a 47% reduction in hospitalization rates, and a 29% reduction in cost.
Medical Research, Clinical Operations
Project
MedinCell is advancing a contraception program funded by the Gates Foundation, which has provided EUR 23 million to support the program through clinical development, with MedinCell retaining all commercial rights to the resulting product.
Clinical Operations
Person-Based
MedinCell News & Media
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext: MEDCL), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for olanzapine long-acting injectable (TEV-‘749) for the treatment of schizophrenia in adults. TEV-‘749 aims to address treatment adherence in real-world settings and contribMedinCell S.A. (MDCLF) Discusses Long-Acting Injectable Platform, R&D Strategy, and Value Creation Approach Transcript
MedinCell S.A. (MDCLF) Discusses Long-Acting Injectable Platform, R&D Strategy, and Value Creation Approach May 12, 2026 10:00 AM EDTCompany...Is It Too Late To Consider MedinCell (ENXTPA:MEDCL) After Its 1 Year 78% Rally?
Wondering whether MedinCell stock still offers value after a strong run, or if the easy gains are behind it, starts with understanding what the current market price is really implying. The stock last closed at €27.06, with returns of 10.4% over 7 days, 16.5% over 30 days, 9.5% year to date, and 77.7% over 1 year. The 3 year and 5 year returns sit at very large multiples of 296.8% and 160.2% respectively. These movesA Look At MedinCell (ENXTPA:MEDCL) Valuation After Its Recent Share Price Momentum
Why MedinCell Stock Is Drawing Investor Attention MedinCell (ENXTPA:MEDCL) is back on many watchlists after a recent share move, with the stock posting a 19.18% gain over the past month and 10.35% over the past 3 months. See our latest analysis for MedinCell. The recent 19.18% 1 month share price return and 6.24% 7 day move come on top of a 69.05% 1 year total shareholder return, suggesting momentum has picked up again after a
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MedinCell
Sign Up For FreeTo access detailed company insights
MedinCell is a clinical- and commercial-stage biopharmaceutical company headquartered in Montpellier, France, focused on developing long-acting injectable treatments across multiple therapeutic areas. Founded in 2003 and publicly traded on Euronext Paris, the company leverages its proprietary BEPO technology platform to enable controlled, sustained... Read More
